AB0416 Early Good Eular Response Predicts Low/Remission Disease State in Rheumatoid Arthritis Patients on Treatment with Certolizumab in Real Life Settings. Data from Italian Registry Gisea

Background Identifying early predictors of sustained clinical response in patients with rheumatoid arthritis (RA) is a major challenge and would have substantial clinical and economic impact. Objectives To evaluate the predicting value of a EULAR good clinical response at 3 months to reach Low Disease Activity (LDA)/Remission in RA patients treated with certolizumab in a standard of care setting. Methods Patients with RA treated with certolizumab because of their active disease included in the GISEA (Gruppo Italiano Studio Early Arthritis) register were prospectively analysed. The first endpoint of this study was to assess the value of 3 a months good EULAR clinical response to predict a LDA, 28-joints Disease Activity Score (DAS28) ≤3.2 or disease remission (DAS28 Results At entry, 278 patients (female 84%) had active disease (DAS28 5.1±1), age 54.8±12 years, mean duration of disease 9.8±8 years, and BMI 25.5±4 kg/m 2 . Certolizumab was given as first ever biological drug in 68% RA patients, and as ≥2 line biological treatment in 32%. The majority of the patients were also assuming glucocorticoids (77%) and 77% were on co-therapy with Disease Modifying Drugs (DMARDs). At 3 months, DAS28 significantly dropped at 4.01±1 and further decreased at 6 (3.2±1) and 12 (3.3±1) months, respectively (p Conclusions This study provided evidence that, in the daily standard of care, RA patients on therapy with certolizumab achieving an early good EULAR response by 3 months maintain the good clinical outcome across 6-12 months, and predicts LDA/disease remission at 6-12 months. Disclosure of Interest None declared